ArticleOncoimmunology2020
Valproic acid attenuates CCR2-dependent tumor infiltration of monocytic myeloid-derived suppressor cells, limiting tumor progression.
Article in Oncoimmunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- LDLRJournal of clinical and translational hepatology · 2026Article
- HDAC1-3 inhibition triggers NEDD4-mediated CCR2 downregulation and attenuates immunosuppression in myeloid-derived suppressor cells.Cancer immunology, immunotherapy : CII · 2025Article
- Epigenetic Regulation of Stromal and Immune Cells and Therapeutic Targets in the Tumor Microenvironment.Biomolecules · 2025Review
- Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies.Journal of cancer research and clinical oncology · 2024Review
- Tumor microenvironment reprogramming by nanomedicine to enhance the effect of tumor immunotherapy.Asian journal of pharmaceutical sciences · 2024Review
- Sodium valproate enhances efficacy of NKG2D CAR-T cells against glioblastoma.Frontiers in immunology · 2024Article
- Review
- Myeloid-derived suppressor cells exacerbate poly(I:C)-induced lung inflammation in mice with renal injury and older mice.Frontiers in immunology · 2023Article
- Surgery-mediated tumor-promoting effects on the immune microenvironment.Seminars in cancer biology · 2022Review
- Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.Pharmacology & therapeutics · 2022Review
- Regulating Histone Deacetylase Signaling Pathways of Myeloid-Derived Suppressor Cells Enhanced T Cell-Based Immunotherapy.Frontiers in immunology · 2022Review
- Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.Frontiers in immunology · 2022Review
- B2M gene expression shapes the immune landscape of lung adenocarcinoma and determines the response to immunotherapy.Immunology · 2021Article
- Targeting Myeloid-Derived Suppressor Cells for Premetastatic Niche Disruption After Tumor Resection.Annals of surgical oncology · 2021Review
- Tumor-related stress regulates functional plasticity of MDSCs.Cellular immunology · 2021Review
- HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression.Oncogene · 2021Article
- Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy.Frontiers in medicine · 2021Article
- Regulatory Effects of Histone Deacetylase Inhibitors on Myeloid-Derived Suppressor Cells.Frontiers in immunology · 2021Review
- Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy.Frontiers in immunology · 2021Review
- MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8Journal of experimental & clinical cancer research : CR · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid-derived suppressor cells (MDSCs) are immunosuppressive cells that promote tumor progression by inhibiting anti-tumor immunity and may be the cause of patient resistance to immune checkpoint inhibitors (ICIs). Therefore, MDSCs are a promising target for cancer immunotherapy, especially in combination with ICIs. Previous studies have shown that the anticonvulsant drug valproic acid (VPA) has additional anti-cancer and immunoregulatory activities due to its inhibition of histone deacetylases. We have previously shown that VPA can attenuate the immunosuppressive function of differentiated MDSCs
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.